

FLAGSHIP BIOSCIENCES: Driving Your Biomarker Strategy

Flagship Biosciences, Inc. uses its computational tissue analysis (cTA®) platform to create rich, contextual biomarker data and strategies that allow pharmaceutical partners to make confident clinical decisions.

Integrated team of scientists, pathologists, tissue analysis experts, data analysts and wet assay and image analysis developers

500+


Projects since 2013, with 6 of 10 of the largest pharmaceutical companies

300+

Studies exploring clinical trial end points and target validation hypotheses

12

US patents supporting our proprietary cTA technology




Research

200+



Target validation/hypothesis testing projects



100+ exploratory clinical trial endpoint projects



100+ qualified IHC and ISH tests

Trials

EARLY



100 singleplex IHC and ISH assays for I/O and DMD studies




10+ multiplex IHC assays for I/O and DMD studies




100+ different cTA solutions for research studies

EFFICACY



10+

Validated assays used as a reported clinical trial endpoint



20+

Validated cTA assay solutions for IHC and ISH

PIVOTAL



10+

LDT and cTA solutions for prospective patient enrollment

